


PHARMACEUTICAL 2022

RenovoRx Inc. Rank 244 of 475





PHARMACEUTICAL 2022

RenovoRx Inc. Rank 244 of 475

The relative strengths and weaknesses of RenovoRx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RenovoRx Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 235% points. The greatest weakness of RenovoRx Inc. is the variable Net Income, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is -102%, being 174% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	16,281
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	938
Liabilities, Non-Current	0
Other Assets	6.0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-653
Property and Equipment	0
Research and Development	3,039
Revenues	0
Selling, General and Administrative Expense	2,632

Output Variable	Value in 1000 USD
Assets	16,287
Liabilities	938
Expenses	5,671
Stockholders Equity	15,349
Net Income	-6,324
Comprehensive Net Income	-6,324
Economic Capital Ratio	-102%